In vivo brain GPCR signaling elucidated by phosphoproteomics
暂无分享,去创建一个
Matthias Mann | Sean J. Humphrey | Yi-Ting Chiu | M. Mann | C. Schwarzer | K. Sharma | Chongguang Chen | L. Liu-Chen | Jeffrey J. Liu | L. Zangrandi | Yi-Ting Chiu | M. Spetea | Kirti Sharma | Chongguang Chen | Lee-Yuan Liu-Chen | Mariana Spetea | Christoph Schwarzer | Luca Zangrandi
[1] J. Kamei,et al. Antipruritic activity of the κ-opioid receptor agonist, TRK-820 , 2002 .
[2] Michael L. Creech,et al. Integration of biological networks and gene expression data using Cytoscape , 2007, Nature Protocols.
[3] Bryan L Roth,et al. Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. , 2009, Biochemistry.
[4] C. Schwarzer. 30 years of dynorphins--new insights on their functions in neuropsychiatric diseases. , 2009, Pharmacology & therapeutics.
[5] A. Lymperopoulos,et al. GPCR signaling and cardiac function. , 2015, European journal of pharmacology.
[6] S. Gygi,et al. Global phosphorylation analysis of β-arrestin–mediated signaling downstream of a seven transmembrane receptor (7TMR) , 2010, Proceedings of the National Academy of Sciences.
[7] Michael L. Eads,et al. Synergistic interactions of endogenous opioids and cannabinoid systems , 1999, Brain Research.
[8] J. Kamei,et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. , 2002, European journal of pharmacology.
[9] L. Bohn,et al. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus , 2015, Neuropharmacology.
[10] L. Bohn,et al. Functional Selectivity of 6′-Guanidinonaltrindole (6′-GNTI) at κ-Opioid Receptors in Striatal Neurons* , 2013, The Journal of Biological Chemistry.
[11] Chao Zhang,et al. CB1 receptor antagonism prevents long-term hyperexcitability after head injury by regulation of dynorphin-KOR system and mGluR5 in rat hippocampus , 2016, Brain Research.
[12] Ryan T. Strachan,et al. Distinct Phosphorylation Sites on the β2-Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of β-Arrestin , 2011, Science Signaling.
[13] Henry Lin,et al. Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.
[14] P. Taghert,et al. Exploring the Biology of G Protein–Coupled Receptors from In Vitro to In Vivo , 2015, Molecular Pharmacology.
[15] Angus C Nairn,et al. Nicotine Regulates DARPP-32 (Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa) Phosphorylation at Multiple Sites in Neostriatal Neurons , 2005, Journal of Pharmacology and Experimental Therapeutics.
[16] K. Inoki,et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.
[17] Ronald F. Mucha,et al. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning , 2004, Psychopharmacology.
[18] M. Bruchas,et al. Stress-Induced p38 Mitogen-Activated Protein Kinase Activation Mediates κ-Opioid-Dependent Dysphoria , 2007, The Journal of Neuroscience.
[19] G. Sperk,et al. Neuropeptide Y and somatostatin immunoreactivity in the rat hippocampus after moderate hypoxia , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.
[20] M. Spetea,et al. Highly Potent and Selective New Diphenethylamines Interacting with the κ-Opioid Receptor: Synthesis, Pharmacology, and Structure–Activity Relationships , 2017, Journal of medicinal chemistry.
[21] S. Eans,et al. Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice , 2017, British journal of pharmacology.
[22] Michael W. Salter,et al. Src kinases: a hub for NMDA receptor regulation , 2004, Nature Reviews Neuroscience.
[23] Mohammad Sayyah,et al. Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. , 2007, Brain : a journal of neurology.
[24] M. Kuśmider,et al. Potential role of G protein-coupled receptor (GPCR) heterodimerization in neuropsychiatric disorders: a focus on depression. , 2013, Pharmacological reports : PR.
[25] W. Colmers,et al. The G‐protein biased partial κ opioid receptor agonist 6′‐GNTI blocks hippocampal paroxysmal discharges without inducing aversion , 2016, British journal of pharmacology.
[26] José A. Dianes,et al. 2016 update of the PRIDE database and its related tools , 2015, Nucleic Acids Res..
[27] T. Shippenberg,et al. Evidence that the aversive effects of opioid antagonists and κ-agonists are centrally mediated , 2004, Psychopharmacology.
[28] Marco Y. Hein,et al. The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.
[29] J. David Sweatt,et al. Roles of serine/threonine phosphatases in hippocampel synaptic plasticity , 2001, Nature Reviews Neuroscience.
[30] J. Coon,et al. Phosphoproteomics in the Age of Rapid and Deep Proteome Profiling , 2015, Analytical chemistry.
[31] Jamie Fong,et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[32] Ruedi Aebersold,et al. Mass-spectrometric exploration of proteome structure and function , 2016, Nature.
[33] D. Bashford,et al. Liu F-NMR 19 by-Adrenergic Receptor Characterized 2 β Biased Signaling Pathways in , 2012 .
[34] Tao Wang,et al. SynaptomeDB: an ontology-based knowledgebase for synaptic genes , 2012, Bioinform..
[35] A. Saria,et al. Conditioned place preference for social interaction in rats: contribution of sensory components , 2011, Front. Behav. Neurosci..
[36] J. Javitch,et al. 6′-Guanidinonaltrindole (6′-GNTI) Is a G Protein-biased κ-Opioid Receptor Agonist That Inhibits Arrestin Recruitment* , 2012, The Journal of Biological Chemistry.
[37] Fahad Saeed,et al. Dynamics of the G Protein-coupled Vasopressin V2 Receptor Signaling Network Revealed by Quantitative Phosphoproteomics* , 2011, Molecular & Cellular Proteomics.
[38] M. Bruchas,et al. Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuits. , 2017, Current opinion in pharmacology.
[39] L. Bohn,et al. β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. , 2014, Handbook of experimental pharmacology.
[40] C. Chen,et al. Cloning of a human kappa opioid receptor from the brain. , 1995, Life sciences.
[41] Kurt Wüthrich,et al. Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.
[42] M. Mann,et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. , 2014, Cell reports.
[43] Matthias Mann,et al. Cell type– and brain region–resolved mouse brain proteome , 2015, Nature Neuroscience.
[44] Bin Zhang,et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..
[45] P. Yadav,et al. Biased agonism at kappa opioid receptors: Implication in pain and mood disorders. , 2015, European journal of pharmacology.
[46] B. Roth,et al. The G Protein–Biased κ-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[47] José A. Dianes,et al. 2016 update of the PRIDE database and its related tools , 2016, Nucleic Acids Res..
[48] M. Mann,et al. Proteomic maps of breast cancer subtypes , 2016, Nature Communications.
[49] Jüergen Cox,et al. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics , 2016, Nature Protocols.
[50] D. Ferguson,et al. Transformation of a κ-Opioid Receptor Antagonist to a κ-Agonist by Transfer of a Guanidinium Group from the 5‘- to 6‘-Position of Naltrindole , 2001 .
[51] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[52] M. Austin,et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[53] Paul Greengard,et al. A phosphatase cascade by which rewarding stimuli control nucleosomal response , 2008, Nature.
[54] Hey-Kyoung Lee,et al. Synaptic plasticity and phosphorylation. , 2006, Pharmacology & therapeutics.
[55] M. Spetea,et al. Discovery and biological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist , 2012, BMC Pharmacology and Toxicology.
[56] Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation , 2016, Molecular Brain.
[57] T. Shippenberg,et al. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. , 1989, Psychopharmacology.
[58] Sean J. Humphrey,et al. Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology. , 2017, Cell metabolism.
[59] Chongguang Chen,et al. Cloning of a human κ opioid receptor from the brain , 1995 .
[60] M. Janech,et al. The β-Arrestin Pathway-selective Type 1A Angiotensin Receptor (AT1A) Agonist [Sar1,Ile4,Ile8]Angiotensin II Regulates a Robust G Protein-independent Signaling Network* , 2011, The Journal of Biological Chemistry.
[61] R. M. Jones,et al. Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. , 2001, Journal of medicinal chemistry.
[62] L. Mansfield,et al. A focus on depression , 2019 .
[63] Sara R. Jones,et al. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria , 2016, Science Signaling.
[64] R. Lahti,et al. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. , 1983, The Journal of pharmacology and experimental therapeutics.
[65] B. Roth,et al. Identification of Novel Functionally Selective κ-Opioid Receptor Scaffolds , 2014, Molecular Pharmacology.
[66] Virginia Chu,et al. Towards the miniaturization of GPCR-based live-cell screening assays. , 2012, Trends in biotechnology.
[67] Allison T. Knoll,et al. Dynorphin, stress, and depression , 2010, Brain Research.
[68] J. Gutkind,et al. G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.
[69] Marco Y. Hein,et al. Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ * , 2014, Molecular & Cellular Proteomics.
[70] A. Heck,et al. Next-generation proteomics: towards an integrative view of proteome dynamics , 2012, Nature Reviews Genetics.
[71] P. Greengard,et al. Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity , 2000, The Journal of Neuroscience.
[72] P. Phillips,et al. Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons , 2015, The Journal of Neuroscience.
[73] R. Hampson,et al. Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons. , 2000, Journal of neurophysiology.
[74] R. Burgoyne,et al. Protein phosphorylation and the regulation of synaptic membrane traffic , 1999, Trends in Neurosciences.
[75] B. Roques,et al. Disruption of the κ‐opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ‐agonist U‐50,488H and attenuates morphine withdrawal , 1998, The EMBO journal.
[76] S. Snyder,et al. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation , 2016, Molecular Psychiatry.
[77] G. Milligan,et al. Deconvolution of complex G protein–coupled receptor signaling in live cells using dynamic mass redistribution measurements , 2010, Nature Biotechnology.
[78] J. Lipton,et al. The Neurology of mTOR , 2014, Neuron.
[79] S. Gammeltoft,et al. Quantitative Phosphoproteomics Dissection of Seven-transmembrane Receptor Signaling Using Full and Biased Agonists* , 2010, Molecular & Cellular Proteomics.
[80] Sean J Humphrey,et al. High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics , 2015, Nature Biotechnology.